Gilead Sciences: Is The Kite Deal Too Little, Too Late?
September 18, 2017 at 11:35 AM EDT
Leerink’s Geoffrey Porges and Bradley Canino raised their price target on the drug maker’s stock to $87 a share, but maintained a Market Perform rating. Here’s why.
